Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bolus vs Continuous Terlipressin in Cirrhotic Septic Shock
NCT04819568Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of terlipressin in septic shock (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Reversal of shock at 72 hours. Status: unknown.
02
Drugs
terlipressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT04819568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819568.